Find Ranirestat manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 147254-64-6, As-3201, Ranirestat [inn], Z26p56gftv, Chembl334830, (3r)-2'-[(4-bromo-2-fluorophenyl)methyl]spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5-tetrone
Molecular Formula
C17H11BrFN3O4
Molecular Weight
420.2  g/mol
InChI Key
QCVNMNYRNIMDKV-QGZVFWFLSA-N
FDA UNII
Z26P56GFTV

Ranirestat
Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels. It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy.
1 2D Structure

Ranirestat

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3R)-2'-[(4-bromo-2-fluorophenyl)methyl]spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5-tetrone
2.1.2 InChI
InChI=1S/C17H11BrFN3O4/c18-10-4-3-9(11(19)6-10)8-21-14(24)12-2-1-5-22(12)17(16(21)26)7-13(23)20-15(17)25/h1-6H,7-8H2,(H,20,23,25)/t17-/m1/s1
2.1.3 InChI Key
QCVNMNYRNIMDKV-QGZVFWFLSA-N
2.1.4 Canonical SMILES
C1C(=O)NC(=O)C12C(=O)N(C(=O)C3=CC=CN23)CC4=C(C=C(C=C4)Br)F
2.1.5 Isomeric SMILES
C1C(=O)NC(=O)[C@@]12C(=O)N(C(=O)C3=CC=CN23)CC4=C(C=C(C=C4)Br)F
2.2 Other Identifiers
2.2.1 UNII
Z26P56GFTV
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazine-4-spiro-3'-pyrrolidine-1.2',3,5'-tetrone

2. As 3201

3. As-3201

4. Sx 3030

5. Sx 3202

6. Sx-3030

7. Sx-3202

2.3.2 Depositor-Supplied Synonyms

1. 147254-64-6

2. As-3201

3. Ranirestat [inn]

4. Z26p56gftv

5. Chembl334830

6. (3r)-2'-[(4-bromo-2-fluorophenyl)methyl]spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5-tetrone

7. Sx-3030

8. (3r)-2'-(4-bromo-2-fluorobenzyl)spiro(pyrrolidine-3,4'(1'h)-pyrrolo(1,2-a)pyrazine)-1',2,3',5(2'h)-tetrone

9. (r)-2'-(4-bromo-2-fluorobenzyl)-1'h-spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5(2'h)-tetraone

10. Unii-z26p56gftv

11. C17h11brfn3o4

12. Raniestat

13. As 3201

14. Sx 3201

15. Ranirestat (jan/inn)

16. Ranirestat [jan]

17. Ranirestat [who-dd]

18. Schembl498993

19. Ranirestat, >=97% (hplc)

20. Dtxsid80163642

21. Zinc598422

22. Bcp14386

23. Bdbm50067407

24. Db05327

25. Sb17385

26. Sx-3201

27. Ncgc00484081-01

28. (r)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone

29. 2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazine-4-spiro-3'-pyrrolidine-1.2',3,5'-tetrone

30. Hy-15314

31. A13523

32. D06403

33. A901889

34. Q7293074

35. (3r)-2''-(4-bromo-2-fluorobenzyl)-1''h,2h,5h-spiro[pyrrolidine-3,4''-pyrrolo[1,2-a]pyrazine]-1'',2,3'',5(2''h)-tetrone

36. (3r)-2-(4-bromo-2-fluorobenzyl)spiro(pyrrolidine-3,4(1h)-pyrrolo(1,2-a)pyrazine)-1,2,3,5(2h)-tetrone

37. (r)-2-(4-bromo-2-fluorobenzyl)-1h-spiro[pyrrolidine-3,4-pyrrolo[1,2-a]pyrazine]-1,2,3,5(2h)-tetraone

38. Spiro(pyrrolidine-3,4'(1'h)-pyrrolo(1,2-a)pyrazine)-1',2,3',5(2'h)-tetrone, 2'-((4-bromo-2-fluorophenyl)methyl)-, (-)-

39. Spiro(pyrrolidine-3,4'(1'h)-pyrrolo(1,2-a)pyrazine)-1',2,3',5(2'h)-tetrone, 2'-((4-bromo-2-fluorophenyl)methyl)-, (3'r)-

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 420.2 g/mol
Molecular Formula C17H11BrFN3O4
XLogP31.3
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count2
Exact Mass418.99170 g/mol
Monoisotopic Mass418.99170 g/mol
Topological Polar Surface Area88.5 Ų
Heavy Atom Count26
Formal Charge0
Complexity689
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Investigated for use/treatment in neuropathy (diabetic).


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Enzyme Inhibitors

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)


5.2 Mechanism of Action

Ranirestat alleviates diabetic neuropathy, a complication of diabetes, by inhibiting aldose reductase and thereby inhibiting the accumulation of intracellular sorbitol that causes diabetic neuropathy. This drug has a stronger inhibitory effect and is longer acting compared to other drugs in this therapeutic area. Ranirestat showed good penetration into the nerve tissue, resulting in dose-dependent inhibition of intraneural accumulation of sorbitol and fructose in a clinical study.


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty